Report cover image

Urinary Incontinence Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146955

Description

Urinary incontinence refers to the involuntary leakage of urine. Factors such as increased body mass index, diabetes, pregnancy, and childbirth are linked with a higher risk of developing urinary incontinence. Studies indicate that around 24% to 45% of women experience urinary incontinence, with 9% to 39% of older women (aged over 60) reporting this condition on a daily basis. Thus, the increasing incidence of urinary incontinence is fuelling the demand for innovative drug solutions. Moreover, the introduction of novel drug delivery systems is expected to improve the efficacy and compliance of urinary incontinence treatments in the coming years.

Report Coverage

The Urinary Incontinence Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into urinary incontinence drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for urinary incontinence. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The urinary incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from urinary incontinence.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to urinary incontinence.

Urinary Incontinence Drug Pipeline Outlook

Urinary incontinence is a loss of bladder control that causes the unintentional passing of urine. In the United Kingdom, it is estimated that 34% of women are affected by urinary incontinence and more than 2 million men experience the condition. Urinary incontinence is associated with an increased risk of hospital acquired urinary tract infections, pressure ulcers, and skin infections, among others.

There are several types of urinary incontinence: mixed, stress, functional, urge, and overflow incontinence. Treatments for urinary incontinence vary depending on the type, severity, and underlying cause. Anticholinergics such as oxybutynin and tolterodine are recommended for overactive bladder to relax the bladder muscles. Topical estrogen is often prescribed to postmenopausal women to improve bladder control. Further, there is a growing R&D investment in novel compounds, biologics, and personalized medicine that can effectively treat urinary incontinence.

Urinary Incontinence – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of urinary incontinence drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Biologics
  • Cell Therapies
  • Gene Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Urinary Incontinence – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials for urinary incontinence.

Urinary Incontinence – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the urinary incontinence pipeline analysis include small molecules, biologics, cell therapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for urinary incontinence.

Urinary Incontinence Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the urinary incontinence drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in urinary incontinence clinical trials:
  • Versameb AG
  • Cook MyoSite
  • EG 427
  • Elidah, Inc.
  • Uromedica
  • Amber Therapeutics Ltd
  • Ethicon, Inc.
  • Neuspera Medical, Inc.
Urinary Incontinence – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Biological: AMDC-USR (iltamiocel)

Sponsored by Cook MyoSite, the objective of this double-blind randomized Phase III study is to compare the efficacy and safety of the autologous muscle derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) with placebo in around 96 female participants with persistent or recurrent stress urinary incontinence post-surgical treatment.

Drug: VMB-100

Versameb AG is conducting a Phase II clinical trial to evaluate the investigational drug VMB-100, an mRNA encoding for IGF-1, for the treatment of moderate stress urinary incontinence. The study has enrolled an estimated 30 female subjects and is expected to be completed by November 2027.

Reasons To Buy This Report

The Urinary Incontinence Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for urinary incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within urinary incontinence pipeline insights.

Key Questions Answered in the Urinary Incontinence – Pipeline Insight Report
  • What is the current landscape of urinary incontinence pipeline drugs?
  • How many companies are developing urinary incontinence drugs?
  • How many phase III and phase IV drugs are currently present in urinary incontinence pipeline drugs?
  • Which companies/institutions are leading the urinary incontinence drug development?
  • What is the efficacy and safety profile of urinary incontinence pipeline drugs?
  • What are the opportunities and challenges present in the urinary incontinence drug pipeline landscape?
  • Which company is conducting major trials for urinary incontinence drugs?
  • What geographies are covered for urinary incontinence clinical trials?
  • What are emerging trends in urinary incontinence clinical trials?
Related Reports

Urinary Incontinence Market

Urinary Incontinence Drugs Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Urinary Incontinence
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Urinary Incontinence
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Urinary Incontinence
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Urinary Incontinence: Epidemiology Snapshot
5.1 Urinary Incontinence Incidence by Key Markets
5.2 Urinary Incontinence – Patients Seeking Treatment in Key Markets
6 Urinary Incontinence: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Urinary Incontinence: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Urinary Incontinence, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Urinary Incontinence Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Urinary Incontinence Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Tolterodine Tartrate ER, Drug: Mirabegron
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Biological: AMDC-USR (iltamiocel)
10.2.3 Other Drugs
11 Urinary Incontinence Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: VMB-100
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: EG110A
11.2.3 Other Drugs
12 Urinary Incontinence Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Biological: Primary human muscle stem cells (Satori-01)
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: Sildenafil
12.2.3 Other Drugs
13 Urinary Incontinence Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Urinary Incontinence, Key Drug Pipeline Companies
14.1 Versameb AG
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Cook MyoSite
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 EG 427
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Elidah, Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Uromedica
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Amber Therapeutics Ltd
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Ethicon, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Neuspera Medical, Inc.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us